Genelux Corp (GNLX) Stock Price & Analysis
Genelux Corp (GNLX) fell 2.36% to USD 2.89 as of July 26, 2026 at 11:06 UTC, according to Nexqual real-time market data.
GNLX last closed at USD 2.96; the session ranged USD 2.85–2.99 on volume of 151,941 shares. Market capitalization is $129.59M, with a 52-week range of USD 2.29–8.54 (NCM). Source: Nexqual, July 26, 2026 at 11:06 UTC.
Key Statistics (as of July 26, 2026 at 11:06 UTC)
| Price | USD 2.89 |
|---|---|
| Change | ▼ 2.36% (down) |
| Previous Close | USD 2.96 |
| Open | USD 2.99 |
| Day Range | USD 2.85 – 2.99 |
| 52-Week Range | USD 2.29 – 8.54 |
| Volume | 151,941 shares |
| Market Cap | $129.59M |
| Exchange | NCM |
Technical Analysis (GNLX)
Nexqual's technical model rates GNLX "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 11:06 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 47.2 (neutral) |
| vs SMA50 | Below (USD 2.95) |
| MACD | -0 (negative) |
Analyst Ratings (GNLX)
Wall Street analysts rate GNLX "None" based on 6 analysts, with a mean price target of USD 17.5 (range USD 10–31), per Nexqual as of July 26, 2026 at 11:06 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 17.5 |
| High Target | USD 31 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (GNLX)
| EPS Estimate | USD -0.2 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.2 vs est -0.2 ▲ beat |
| 2025-12-31 | USD -0.24 vs est -0.22 ▼ miss |
| 2025-09-30 | USD -0.21 vs est -0.21 ▲ beat |
| 2025-06-30 | USD -0.2 vs est -0.22 ▲ beat |
Source: Nexqual, July 26, 2026 at 11:06 UTC.
Financials & Fundamentals (GNLX)
| Total Revenue | $8,000 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -432112.50% |
| Profit Margin | +0.00% |
| ROE | -127.28% |
| Debt / Equity | 10.89 |
| Current Ratio | 3.68 |
| Total Cash | $26.21M |
| Total Debt | $2.50M |
| Free Cash Flow | $-15.33M |
Source: Nexqual, July 26, 2026 at 11:06 UTC.
Financial Health Score (GNLX)
Nexqual rates Genelux Corp's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 11:06 UTC.
| Growth | Mixed — Revenue +0.0% YoY (annual), slow |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $26M cash vs $2M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$15M, burning cash |
| Efficiency | Critical — ROE -127%, ROA -60.6% |
Ownership (GNLX)
| Insider Ownership | +13.12% |
|---|---|
| Institutional Ownership | +30.74% |
| Shares Outstanding | 44.84M |
| Float | 36.13M |
| Short % of Float | +7.15% |
Source: Nexqual, July 26, 2026 at 11:06 UTC.
Leadership (GNLX)
Genelux Corp is led by Thomas D. Zindrick (age 65), Chairman, CEO & President, per Nexqual as of July 26, 2026 at 11:06 UTC.
| Chairman, CEO & President | Thomas D. Zindrick (age 65) |
|---|---|
| CFO and Principal Financial & Accounting Officer | Matthew Pulisic (age 41) |
| Chief Scientific Officer | Yong Yu (age 53) |
Major Backers & Investors (GNLX)
Notable institutional backers of Genelux Corp include Woodward Diversified Capital, LLC, Bleichroeder LP, Fidelity, according to Nexqual as of July 26, 2026 at 11:06 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Woodward Diversified Capital, LLC | 4.72% |
| Bleichroeder LP | 3.08% |
| Fidelity | 0.8% |
| Bank of America Corporation | 0.72% |
| FLPutnam Investment Management Company | 0.63% |
| CM Management, LLC | 0.56% |
| Global Retirement Partners, LLC | 0.48% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.05% |
| BlackRock | 1.14% |
| Geode Capital | 1.01% |
Source: Nexqual, July 26, 2026 at 11:06 UTC.
From Genelux Corp's Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
- Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
- It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates.
- The company has a licensing agreement with Newsoara BioPharma Co.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SGMT | Sagimet Biosciences Inc. - Seri | USD 7.07 | ▲ 0.28% |
| AZTR | Azitra Inc | USD 0.13 | ▼ 3.08% |
| EUDA | Euda Health Holdings Limited | USD 14.99 | ▲ 7.07% |
| SRZN | Surrozen, Inc. | USD 19.73 | ▼ 9.16% |
| INAB | IN8bio, Inc. | USD 1.2 | ▼ 2.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 11:06 UTC. This page is informational and not investment advice.